[HTML][HTML] Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
E van Diest, PH López, AD Meringa… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background γ9δ2 T cells hold great promise as cancer therapeutics because of their unique
capability of reacting to metabolic changes with tumor cells. However, it has proven very …
capability of reacting to metabolic changes with tumor cells. However, it has proven very …